GLPwatch
[Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
Rev Med Liege · 2019
Last updated 2026-05-28Suliqua® combines two diabetes medications—insulin glargine and lixisenatide—in a single injection to improve blood sugar control. Studies show it lowers blood sugar more effectively than either medication alone, with 40% of patients reaching target blood sugar levels compared to 20% with insulin alone. It also helps with weight management and has fewer side effects than taking lixisenatide alone. The medication comes in two doses, allowing for personalized treatment.
AI summary of the abstract below.
| Journal | Rev Med Liege, 2019 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | lixisenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Suliqua® (iGlarLixi) is a fixed ratio combination of basal insulin glargine U100 and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide. Both molecules exert complementary antihyperglycaemic effects : insulin glargine mainly targets fasting glycaemia while lixisenatide mainly targets postprandial hyperglycaemia. Thus, iGlarLixi is associated with a greater reduction in glycated haemoglobin (HbA1c) than each individual component and thereby results in a greater percentage of patients reaching HbA1c ? 7 %. It has a good tolerance profile, with a more favourable effect on body weight compared with insulin glargine alone and less gastrointestinal adverse effects when compared with lixisenatide alone, because of a more progressive titration of the GLP-1 receptor agonist component. iGlarLixi (Suliqua®) is presented as two different prefilled pens, one allowing to titrate glargine up to 40 IU/day, the other up to 60 IU/day, both with lixisenatide uptitrated to a maximum of 20 µg/day. This dual presentation facilitates a personalized approach according to patient's needs. Suliqua® is currently reimbursed, under conditions, for the management of type 2 diabetes not well controlled with basal insulin associated or not with oral antidiabetic agents.
Verbatim abstract via PubMed 30793566 ↗
Related research
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
- Trial of Lixisenatide in Early Parkinson's Disease.
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.